combined allergic rhinitis and asthma syndrome
Conditions
Interventions
control group:Mometasone furoate nasal spray + inhalation of budesonide/formoterol powder inhalation + oral Tongqiao Pingchuan decoction granule mimics
experimental group:Mometasone furoate nasal spray + budesonide/formoterol powder inhalation + Tongqiao Pingchuan decoction granules orally
Sponsors
Shanghai Municipal Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
6 Years to 11 Years
Inclusion criteria
Inclusion criteria: (1) The patients were 6-11 years old (< 12 years old), male or female, and came from the outpatient department. (2) The diagnostic criteria of CARAS in children were in accordance with the "Recommendations for the Standardized diagnosis and Treatment of Bronchial Asthma in Children (2020)" and the "Guidelines for the diagnosis and treatment of allergic rhinitis in Children (2022, Revised edition)". (3) Rhinitis was mild AR or intermittent moderate to severe AR; Asthma was in the non-acute stage, and the condition was mild persistent (level 2) and moderate persistent (level 3). (4) in accordance with the TCM syndrome of pathogenic wind invading the lung; (5) in accordance with the provisions of informed consent.
Exclusion criteria
Exclusion criteria: (1) children with nasal septum curvature, nasal polyps, sinusitis, abnormal nasal anatomy or other respiratory diseases; (2) other diseases causing asthma or dyspnea; (3) Patients with inadequate washout period before enrollment: 1) patients received immunotherapy within 1 month; 2) Systemic use of glucocorticoids within 2 weeks; 4) Systemic use of leukotriene receptor antagonists, theophyllines, or long-acting anticholinergic drugs within one week; 3) Systemic use of antihistamines within 5 days; 5) use of nasal decongestants and antihistamines within 3 days; (4) combined with cardiovascular and cerebrovascular diseases, hematopoietic system diseases, or serious diseases of other organs, such as heart, liver, kidney and other diseases; (5) patients with mental disorders, severe malnutrition and rickets; (6) patients with known allergies to the drugs used in this study (7)Any situation that the investigator believes would compromise patient safety or data quality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM single symptom and syndrome scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms of asthma exacerbations were recorded;FnNO;The CARATkids test;The TNSS test;Percentage of eosinophils;lung function;Cumulative drug dosage;The C-ACT test; | — |
Countries
CHINA
Contacts
Public ContactXue Zheng
Shanghai Municipal Hospital of Traditional Chinese Medicine
Outcome results
None listed